You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

LOTEMAX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Lotemax

A generic version of LOTEMAX was approved as loteprednol etabonate by SENTISS on April 17th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOTEMAX?
  • What are the global sales for LOTEMAX?
  • What is Average Wholesale Price for LOTEMAX?
Drug patent expirations by year for LOTEMAX
Drug Prices for LOTEMAX

See drug prices for LOTEMAX

Drug Sales Revenue Trends for LOTEMAX

See drug sales revenues for LOTEMAX

Recent Clinical Trials for LOTEMAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Thomas Chester, ODPhase 4
Illinois College of OptometryEarly Phase 1
Dr Salouti Eye Research CenterPhase 4

See all LOTEMAX clinical trials

Pharmacology for LOTEMAX

US Patents and Regulatory Information for LOTEMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc LOTEMAX loteprednol etabonate GEL;OPHTHALMIC 202872-001 Sep 28, 2012 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmos LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020841-001 Mar 9, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb LOTEMAX loteprednol etabonate OINTMENT;OPHTHALMIC 200738-001 Apr 15, 2011 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020583-001 Mar 9, 1998 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOTEMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020583-001 Mar 9, 1998 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc LOTEMAX loteprednol etabonate GEL;OPHTHALMIC 202872-001 Sep 28, 2012 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020583-001 Mar 9, 1998 ⤷  Sign Up ⤷  Sign Up
Pharmos LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020841-001 Mar 9, 1998 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020583-001 Mar 9, 1998 ⤷  Sign Up ⤷  Sign Up
Pharmos LOTEMAX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020841-001 Mar 9, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LOTEMAX

See the table below for patents covering LOTEMAX around the world.

Country Patent Number Title Estimated Expiration
Japan 3570720 ⤷  Sign Up
South Korea 20000070492 ⤷  Sign Up
Austria 379816 ⤷  Sign Up
Spain 8306767 ⤷  Sign Up
France 2486529 ⤷  Sign Up
Canada 1174667 STEROIDES DOUX AYANT DES PROPRIETES ANTI- INFLAMMATOIRES (SOFT STEROIDS HAVING ANTI-INFLAMATORY ACTIVITY) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.